Paul M. Steven's most recent trade in Rapport Therapeutics Inc. was a trade of 21,850 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 17, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Rapport Therapeutics Inc. | Steven M. Paul | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2025 | 21,850 | 21,850 | - | - | Stock Option (Right to Buy) | |
| Karuna Therapeutics Inc | Steven M. Paul | Director | Other type of transaction at price $ 315.18 per share. | 29 Feb 2024 | 47,378 | 70,608 (0%) | 0% | 315.2 | 14,932,598 | Common Stock |
| Karuna Therapeutics Inc | Steven M. Paul | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 29 Feb 2024 | 30,304 | 30,304 (0%) | 0% | 0 | Common Stock | |
| Karuna Therapeutics Inc | Steven M. Paul | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 29 Feb 2024 | 30,304 | 2,364 (0%) | 0% | 0 | Common Stock | |
| Karuna Therapeutics Inc | Steven M. Paul | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 29 Feb 2024 | 30,304 | 32,668 (0%) | 0% | 0 | Common Stock | |
| Karuna Therapeutics Inc | Steven M. Paul | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 29 Feb 2024 | 30,304 | 10,000 (0%) | 0% | 0 | Common Stock | |
| Karuna Therapeutics Inc | Steven M. Paul | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 29 Feb 2024 | 30,304 | 30,304 (0%) | 0% | 0 | Common Stock | |
| Karuna Therapeutics Inc | Steven M. Paul | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 29 Feb 2024 | 30,304 | 40,304 (0%) | 0% | 0 | Common Stock | |
| Karuna Therapeutics Inc | Paul M. Steven | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2024 | 27,510 | 757,045 | - | - | Option (right to buy) | |
| Karuna Therapeutics Inc | Steven M. Paul | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.27 per share. | 23 Feb 2024 | 27,510 | 38,106 (0%) | 0% | 7.3 | 199,998 | Common Stock |
| Karuna Therapeutics Inc | Steven Paul M. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 99.72 per share. | 23 Feb 2024 | 4,008 | 42,114 (0%) | 0% | 99.7 | 399,678 | Common Stock |
| Karuna Therapeutics Inc | Paul M. Steven | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2024 | 4,008 | 135,992 | - | - | Option (right to buy) | |
| Karuna Therapeutics Inc | Paul Steven M. | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 317.14 per share. | 09 Feb 2024 | 804 | 10,596 (0%) | 0% | 317.1 | 254,981 | Common Stock |
| Sage Therapeutics Inc | Steven M. Paul | Director | 09 Nov 2021 | 1 | 1 (0%) | 0% | 43 | 43 | Common Stock | |
| Karuna Therapeutics Inc | Steven M. Paul | Director, PRESIDENT CEO | Purchase of securities on an exchange or from another person at price $ 105.63 per share. | 17 Aug 2021 | 1,183 | 107,668 (0%) | 0% | 105.6 | 124,960 | Common Stock |
| Karuna Therapeutics Inc | Steven M. Paul | Director, PRESIDENT CEO | Purchase of securities on an exchange or from another person at price $ 106.10 per share. | 17 Aug 2021 | 1,181 | 108,849 (0%) | 0% | 106.1 | 125,304 | Common Stock |
| Alnylam Pharmaceuticals Inc | Steven M. Paul | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2021 | 4,032 | 4,032 | - | - | Stock Option (right to buy) | |
| Sage Therapeutics Inc | Steven M. Paul | Director | 10 Jun 2021 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | ||
| Voyager Therapeutics Inc | Steven M. Paul | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2021 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Karuna Therapeutics Inc | Steven M. Paul | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2021 | 161,850 | 161,850 | - | - | Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Steven M. Paul | Director | Sale of securities on an exchange or to another person at price $ 140.00 per share. | 18 Dec 2020 | 15,000 | 1,000 (0%) | 0% | 140 | 2,100,000 | Common Stock |
| Alnylam Pharmaceuticals Inc | Steven M. Paul | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.30 per share. | 18 Dec 2020 | 15,000 | 16,000 (0%) | 0% | 9.3 | 139,500 | Common Stock |
| Alnylam Pharmaceuticals Inc | Steven M. Paul | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Dec 2020 | 15,000 | 0 | - | - | Stock Option (right to buy) |